• Login
    View Item 
    •   Home
    • Articles and other publications by RIVM employees
    • Miscellaneous
    • View Item
    •   Home
    • Articles and other publications by RIVM employees
    • Miscellaneous
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    RIVM Publications RepositoryCommunitiesTitleAuthorsIssue DateSubmit Date

    My Account

    LoginRegister

    Statistics

    Display statistics

    Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Publisher version
    View Source
    Access full-text PDFOpen Access
    View Source
    Check access options
    Check access options
    Average rating
     
       votes
    Cast your vote
    You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.
    Star rating
     
    Your vote was cast
    Thank you for your feedback
    Authors
    Debrie, Anne-Sophie
    Coutte, Loïc
    Raze, Dominique
    Mooi, Frits
    Alexander, Frances
    Gorringe, Andrew
    Mielcarek, Nathalie
    Locht, Camille
    Type
    Article
    Language
    en
    
    Metadata
    Show full item record
    Title
    Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Published in
    Vaccine 2018; 36(11):1345-52
    Publiekssamenvatting
    Pertussis or whooping cough is currently the most prevalent vaccine-preventable childhood disease despite >85% global vaccination coverage. In recent years incidence has greatly increased in several high-income countries that have switched from the first-generation, whole-cell vaccine to the newer acellular vaccines, calling for improved vaccination strategies with better vaccines. We have developed a live attenuated pertussis vaccine candidate, called BPZE1, which is currently in clinical development. Unlike other pertussis vaccines, BPZE1 has been shown to provide strong protection against infection by the causative agent of pertussis, Bordetella pertussis, in non-human primates. BPZE1 is a derivative of the B. pertussis strain Tohama I, which produces serotype 2 (Fim2) but not serotype 3 fimbriae (Fim3). As immune responses to fimbriae are likely to contribute to protection, we constructed a BPZE1 derivative, called BPZE1f3, that produces both serotypes of fimbriae. Whereas nasal vaccination of mice with BPZE1 induced antibodies to Fim2 but not to Fim3, vaccination with BPZE1f3 elicited antibodies to both Fim2 and Fim3 at approximately the same level. In mice, both BPZE1 and BPZE1f3 provided equal levels of protection against clinical isolates that either produce Fim2 alone, both Fim2 and Fim3, or no fimbriae. However, vaccination with BPZE1f3 provided significantly stronger protection against Fim3-only producing B. pertussis than vaccination with BPZE1, indicating that immune responses to fimbriae contribute to serotype-specific protection against B. pertussis infection.
    DOI
    10.1016/j.vaccine.2018.02.017
    PMID
    29433898
    URI
    http://hdl.handle.net/10029/621432
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.vaccine.2018.02.017
    Scopus Count
    Collections
    Miscellaneous

    entitlement

    Related articles

    • Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
    • Authors: Heikkinen E, Xing DK, Olander RM, Hytönen J, Viljanen MK, Mertsola J, He Q
    • Issue date: 2008 Sep 25
    • Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
    • Authors: Hallander H, Advani A, Alexander F, Gustafsson L, Ljungman M, Pratt C, Hall I, Gorringe AR
    • Issue date: 2014 Feb
    • Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    • Authors: Queenan AM, Dowling DJ, Cheng WK, Faé K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, Wiertsema S, Fortanier A, van den Dobbelsteen G, Levy O, Poolman J
    • Issue date: 2019 Jan 3
    • Bordetella pertussis fimbriae (Fim): relevance for vaccines.
    • Authors: Gorringe AR, Vaughan TE
    • Issue date: 2014 Oct
    • Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
    • Authors: Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, Gustafsson L
    • Issue date: 2009 Sep

    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.